1/17/2024 0 Comments Pfizer covid vaccine infographicNot only is there significant economic incentive now for this on the continent, but it will also avoid the effects of richer countries hoarding resources, while improving future access to innovation, such as new treatments and diagnostics for the health challenges of the future. Second, albeit highly dependent on the above, Africa must grow its vaccine and therapeutics manufacturing capacity, including beyond fill-and-finish facilities to include API production – and build the associated expertise necessary. How many lives will be lost in this 6-month period, or longer? We present a panel dataset of COVID-19 vaccine policies, with data from 01 January 2020 for 185 countries and a number of subnational jurisdictions, reporting on vaccination prioritization plans. Yet, these are literally life and death issues. An overview of the epidemiology and burden of COVID-19 in children 5 to 11 years old, including benefits of vaccination, pediatric Pfizer-BioNTech Comirnaty. In the end, the decision settled on offering limited waivers for vaccines, but excluded trade secrets and manufacturing methods, and deferred waivers for therapeutics and other essential items for another 6 months. However, African publics saw a disappointing end to the June 2022 WTO negotiations on a proposal to waive IP rights. Of course, this kind of cost is beyond the reach of most low- and middle-income countries, including in Africa.įirst, the world must move in the direction of enabling local production by enabling more sub-licencing and generics production, to permit the rapid sharing and proliferation of treatment options for the most vulnerable countries and populations. This makes these original versions of drugs very expensive – over 500 USD for just one course of treatment for both types. Our infographics have continually demonstrated the continued efforts of African governments to secure vaccines for their populations, despite hoarding elsewhere. Producing these drugs requires licensing agreements, because the firms that produce them -Pfizer and Merck-Ridgeback – have sought Intellectual Property (IP) protection through international patents, introduced through the World Trade Organisation (WTO) under an agreement known as Trade-Related Intellectual Property Rights (TRIPS) (as an aside – this history of TRIPS is essential reading for both the un-inititiated and initiated!). Both can be administered as oral tablets, making them convenient for prescription use at home by individuals, with efficacy rates of 89% and 30% respectively. However, two treatments of note have now passed the World Health Organisation Emergency Use Authorization (EUA) muster: the Pfizer brand PAXLOVID and Merck-Ridgeback Biotherapeutics LAGVERIO. ![]() Most of the medicines that could be used this way are still being assessed for efficacy and safety and are strictly for use in mild-moderate cases where hospitalization is a risk.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |